| Catalog No. | Size | Price (USD) |
| 10101-MM04-50 | 50 µL | $147.96 |
| 10101-MM04-100 | 100 µL | $251.64 |
| 10101-MM04-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-CD55/DAF Antibody, Mouse Monoclonal |
| Validated applications | FCM (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CD55/DAF |
| Immunogen | Recombinant Human CD55 / DAF Protein (Catalog#10101-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD55 / DAF (rh CD55 / DAF; Catalog#10101-H08H; NP_000565.1; Met1-Ser353). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #04 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-CHAPLE Antibody; Anti-CR Antibody; Anti-CROM Antibody; Anti-DAF Antibody; Anti-TC Antibody
Image / Experimental Information
| Image 1 Description | Flow cytometric analysis of Human CD55 expression on K562 cells. Cells were stained with purified anti-Human CD55, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Image 1 Alt Text | Human CD55/DAF Flow Cytometry (FC) 5249 |
| Image 1 URL | Source image |
Background Information
| Full Name | CD55 molecule, decay accelerating factor for complement (Cromer blood group) |
| Description | CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology. |
| Related Pathways |
|
| References |
|
